Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
STARD13 encodes a protein which contains an N-terminal sterile alpha motif (SAM) for protein-protein interactions, followed by an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a C-terminal STAR-related lipid transfer (START) domain. Additionally we are shipping STARD13 Proteins (3) and STARD13 Kits (2) and many more products for this protein.
Showing 10 out of 27 products:
Human Polyclonal STARD13 Primary Antibody for WB - ABIN1881846
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 2 Pubmed References
role of miR (show MLXIP Antibodies)-125b in pro-metastasis by targeting STARD13
DLC2 (show DYNLL2 Antibodies) plays a key role in pain modulation during inflammation by suppressing the activation of RhoA (show RHOA Antibodies) and ERK (show EPHB2 Antibodies) to prevent an exaggerated pain response
Results suggest that DLC2 (show DYNLL2 Antibodies) exhibits its tumor suppressor functions in vivo as a GAP specific for RhoA (show RHOA Antibodies), exerting its effects in suppression of cytoskeleton reorganization, cell growth, cell migration, and transformation.
Low STARD13 expression is associated with metastasis of breast cancer.
miR (show MLXIP Antibodies)-125b functions as an oncogene (show RAB1A Antibodies) in gastric cancer and represents a new potential therapeutic target for gastric cancer.
The tumor suppressor DLC2 and Kif1B (show KIF1B Antibodies) are central components of a signaling network that guides spindle positioning, cell-cell adhesion and mitotic fidelity.
Dimerization of DLC2 was required for its interaction with GKAP (show DLGAP1 Antibodies), which, in turn, potentiated GKAP (show DLGAP1 Antibodies) self-association.
Study describes STARD13 as a tumor suppressor playing a positive role in cancer motility.
The present study further describes the role of StarD13 as a tumor suppressor as well as a Rho GAP (show ARHGAP36 Antibodies).
Importance of the regulation of RhoA (show RHOA Antibodies) activity in focal adhesions of astrocytoma cells and StarD13 is a GAP playing a major role in this process.
In the present review, we discuss the family of RhoGTPases, their regulation and their RhoGAPs, focusing mainly on STARD13. [review]
RhoGAP protein (show ARHGAP26 Antibodies) Stard13 is an essential regulator of pancreas tissue architecture in the mammalian embryo; Stard13 acts by regulating Rho signalling spatially and temporally during pancreas development.
Authors detected an increase in p-ERK (show EPHB2 Antibodies) in StarD13 knockdown cells, uncovering a potential link between Rho GTPases and ERK (show EPHB2 Antibodies) activation.
This gene encodes a protein which contains an N-terminal sterile alpha motif (SAM) for protein-protein interactions, followed by an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a C-terminal STAR-related lipid transfer (START) domain. It may be involved in regulation of cytoskeletal reorganization, cell proliferation, and cell motility, and acts as a tumor suppressor in hepatoma cells. The gene is located in a region of chromosome 13 that is associated with loss of heterozygosity in hepatocellular carcinomas. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.
rho GTPase-activating protein 32
, START domain-containing protein 13
, serologically defined colon cancer antigen 13
, serologically defined colon cancer antigen 28
, stAR-related lipid transfer protein 13
, Rho GTPase activating protein on chromosome 13q12
, deleted in liver cancer 2 protein
, long intergenic non-protein coding RNA 464